Wednesday, January 26, 2022

First commercial production in Biocatalysts’ new enzyme manufacturing facility

Speciality enzyme company, Biocatalysts Ltd, has delivered the first customer product that was fermented and processed in its state-of-the-art enzyme manufacturing facility.

The unique enzyme was scaled up and commercialised in less than 10 months to meet the demands of the customers’ manufacturing schedule.

It is a testament to the team that the plant commissioning, validation, and production of the first commercial product was done during these unprecedented times and shows Biocatalysts Ltd.’s commitment to providing large-scale fermentation services.

To ensure a reliable and robust service the manufacturing facility has been designed to deliver a unique, fully automated ‘LEAN’ manufacturing process, ensuring maximum yield recovery at every stage of the process.

The extension is capable of E. coli, Pichia and Yarrowia fermentations and subsequent down-stream-processing. The new fermentation capacity increases its existing portfolio, extending its fermentation scales to 3L, 75L, 750L and 10,000L and has been designed to accommodate future growth.

The whole process is controlled by state-of-the-art Siemens software to maximise capacity and enhance efficiencies, guaranteeing world-class support and service.

Coupled with its award-winning enzyme discovery, development and manufacturing process Biocatalysts Ltd truly have a unique breadth of offering in the biotechnology marketplace.

Craig Galeozzie, Director of Operations at Biocatalysts Ltd, commented: “The strategic planning, design and subsequent installation has been an incredible 3-year journey, ultimately delivering a conceptual ‘LEAN’ process that provides us with a unique facility unrivalled in the industry.

“Built on the foundations of teamwork, the extension project is another example of the extraordinary commitment, professionalism and dedication of our staff to exceed our customers’ expectations as we further develop the facility and strengthen our marketability.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemic having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.

Latest news

Related news

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.